Selected research
Market Analysis & Forecast
Global mRNA Vaccine Drugs Development Services Market Analysis and Forecast 2026-2032
Market perspective
The global mRNA Vaccine Drugs Development Services market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for mRNA Vaccine Drugs Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for mRNA Vaccine Drugs Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for mRNA Vaccine Drugs Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for mRNA Vaccine Drugs Development Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of mRNA Vaccine Drugs Development Services include ReciBioPharm, Merck, Samsung Biologics, Thermo Fisher Scientific, Lonza, Ricoh Group, Aldevron, Wuxi Biologics and Genscript Probio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for mRNA Vaccine Drugs Development Services, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of mRNA Vaccine Drugs Development Services, also provides the revenue of main regions and countries. Of the upcoming market potential for mRNA Vaccine Drugs Development Services, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the mRNA Vaccine Drugs Development Services revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global mRNA Vaccine Drugs Development Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for mRNA Vaccine Drugs Development Services revenue, projected growth trends, production technology, application and end-user industry.
mRNA Vaccine Drugs Development Services Segment by Company
ReciBioPharm
Merck
Samsung Biologics
Thermo Fisher Scientific
Lonza
Ricoh Group
Aldevron
Wuxi Biologics
Genscript Probio
Novoprotein
Porton Advanced Solutions
Precision NanoSystems
mRNA Vaccine Drugs Development Services Segment by Type
mRNA Process Development Services
mRNA Synthesis Services
mRNA Drug Substance Purification Services
Others
mRNA Vaccine Drugs Development Services Segment by Application
Non-Replicating mRNA Vaccine Drugs
Self-Amplifying mRNA Vaccine Drugs
mRNA Vaccine Drugs Development Services Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccine Drugs Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccine Drugs Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccine Drugs Development Services.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of mRNA Vaccine Drugs Development Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of mRNA Vaccine Drugs Development Services company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Vaccine Drugs Development Services revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- mRNA Process Development Services
- mRNA Synthesis Services
- mRNA Drug Substance Purification Services
- Others
Applications
- Non-Replicating mRNA Vaccine Drugs
- Self-Amplifying mRNA Vaccine Drugs
Companies covered
- ReciBioPharm
- Merck
- Samsung Biologics
- Thermo Fisher Scientific
- Lonza
- Ricoh Group
- Aldevron
- Wuxi Biologics
- Genscript Probio
- Novoprotein
- Porton Advanced Solutions
- Precision NanoSystems
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 mRNA Vaccine Drugs Development Services Market by Type
- 1.2.1 Global mRNA Vaccine Drugs Development Services Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 mRNA Process Development Services
- 1.2.3 mRNA Synthesis Services
- 1.2.4 mRNA Drug Substance Purification Services
- 1.2.5 Others
- 1.3 mRNA Vaccine Drugs Development Services Market by Application
- 1.3.1 Global mRNA Vaccine Drugs Development Services Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Non-Replicating mRNA Vaccine Drugs
- 1.3.3 Self-Amplifying mRNA Vaccine Drugs
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 mRNA Vaccine Drugs Development Services Market Dynamics
- 2.1 mRNA Vaccine Drugs Development Services Industry Trends
- 2.2 mRNA Vaccine Drugs Development Services Industry Drivers
- 2.3 mRNA Vaccine Drugs Development Services Industry Opportunities and Challenges
- 2.4 mRNA Vaccine Drugs Development Services Industry Restraints
3 Global Growth Perspective
- 3.1 Global mRNA Vaccine Drugs Development Services Market Perspective (2021-2032)
- 3.2 Global mRNA Vaccine Drugs Development Services Growth Trends by Region
- 3.2.1 Global mRNA Vaccine Drugs Development Services Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global mRNA Vaccine Drugs Development Services Market Size by Region (2021-2026)
- 3.2.3 Global mRNA Vaccine Drugs Development Services Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global mRNA Vaccine Drugs Development Services Revenue by Players
- 4.1.1 Global mRNA Vaccine Drugs Development Services Revenue by Players (2021-2026)
- 4.1.2 Global mRNA Vaccine Drugs Development Services Revenue Market Share by Players (2021-2026)
- 4.1.3 Global mRNA Vaccine Drugs Development Services Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global mRNA Vaccine Drugs Development Services Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global mRNA Vaccine Drugs Development Services Key Players Headquarters & Area Served
- 4.4 Global mRNA Vaccine Drugs Development Services Players, Product Type & Application
- 4.5 Global mRNA Vaccine Drugs Development Services Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global mRNA Vaccine Drugs Development Services Market CR5 and HHI
- 4.6.3 2025 mRNA Vaccine Drugs Development Services Tier 1, Tier 2, and Tier 3
5 mRNA Vaccine Drugs Development Services Market Size by Type
- 5.1 Global mRNA Vaccine Drugs Development Services Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global mRNA Vaccine Drugs Development Services Revenue by Type (2021-2032)
- 5.3 Global mRNA Vaccine Drugs Development Services Revenue Market Share by Type (2021-2032)
6 mRNA Vaccine Drugs Development Services Market Size by Application
- 6.1 Global mRNA Vaccine Drugs Development Services Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global mRNA Vaccine Drugs Development Services Revenue by Application (2021-2032)
- 6.3 Global mRNA Vaccine Drugs Development Services Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 ReciBioPharm
- 7.1.1 ReciBioPharm Company Information
- 7.1.2 ReciBioPharm Business Overview
- 7.1.3 ReciBioPharm mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.1.4 ReciBioPharm mRNA Vaccine Drugs Development Services Product Portfolio
- 7.1.5 ReciBioPharm Recent Developments
- 7.2 Merck
- 7.2.1 Merck Company Information
- 7.2.2 Merck Business Overview
- 7.2.3 Merck mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.2.4 Merck mRNA Vaccine Drugs Development Services Product Portfolio
- 7.2.5 Merck Recent Developments
- 7.3 Samsung Biologics
- 7.3.1 Samsung Biologics Company Information
- 7.3.2 Samsung Biologics Business Overview
- 7.3.3 Samsung Biologics mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.3.4 Samsung Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 7.3.5 Samsung Biologics Recent Developments
- 7.4 Thermo Fisher Scientific
- 7.4.1 Thermo Fisher Scientific Company Information
- 7.4.2 Thermo Fisher Scientific Business Overview
- 7.4.3 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.4.4 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Product Portfolio
- 7.4.5 Thermo Fisher Scientific Recent Developments
- 7.5 Lonza
- 7.5.1 Lonza Company Information
- 7.5.2 Lonza Business Overview
- 7.5.3 Lonza mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.5.4 Lonza mRNA Vaccine Drugs Development Services Product Portfolio
- 7.5.5 Lonza Recent Developments
- 7.6 Ricoh Group
- 7.6.1 Ricoh Group Company Information
- 7.6.2 Ricoh Group Business Overview
- 7.6.3 Ricoh Group mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.6.4 Ricoh Group mRNA Vaccine Drugs Development Services Product Portfolio
- 7.6.5 Ricoh Group Recent Developments
- 7.7 Aldevron
- 7.7.1 Aldevron Company Information
- 7.7.2 Aldevron Business Overview
- 7.7.3 Aldevron mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.7.4 Aldevron mRNA Vaccine Drugs Development Services Product Portfolio
- 7.7.5 Aldevron Recent Developments
- 7.8 Wuxi Biologics
- 7.8.1 Wuxi Biologics Company Information
- 7.8.2 Wuxi Biologics Business Overview
- 7.8.3 Wuxi Biologics mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.8.4 Wuxi Biologics mRNA Vaccine Drugs Development Services Product Portfolio
- 7.8.5 Wuxi Biologics Recent Developments
- 7.9 Genscript Probio
- 7.9.1 Genscript Probio Company Information
- 7.9.2 Genscript Probio Business Overview
- 7.9.3 Genscript Probio mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.9.4 Genscript Probio mRNA Vaccine Drugs Development Services Product Portfolio
- 7.9.5 Genscript Probio Recent Developments
- 7.10 Novoprotein
- 7.10.1 Novoprotein Company Information
- 7.10.2 Novoprotein Business Overview
- 7.10.3 Novoprotein mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.10.4 Novoprotein mRNA Vaccine Drugs Development Services Product Portfolio
- 7.10.5 Novoprotein Recent Developments
- 7.11 Porton Advanced Solutions
- 7.11.1 Porton Advanced Solutions Company Information
- 7.11.2 Porton Advanced Solutions Business Overview
- 7.11.3 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.11.4 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Product Portfolio
- 7.11.5 Porton Advanced Solutions Recent Developments
- 7.12 Precision NanoSystems
- 7.12.1 Precision NanoSystems Company Information
- 7.12.2 Precision NanoSystems Business Overview
- 7.12.3 Precision NanoSystems mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
- 7.12.4 Precision NanoSystems mRNA Vaccine Drugs Development Services Product Portfolio
- 7.12.5 Precision NanoSystems Recent Developments
8 North America
- 8.1 North America mRNA Vaccine Drugs Development Services Revenue (2021-2032)
- 8.2 North America mRNA Vaccine Drugs Development Services Revenue by Type (2021-2032)
- 8.2.1 North America mRNA Vaccine Drugs Development Services Revenue by Type (2021-2026)
- 8.2.2 North America mRNA Vaccine Drugs Development Services Revenue by Type (2027-2032)
- 8.3 North America mRNA Vaccine Drugs Development Services Revenue Share by Type (2021-2032)
- 8.4 North America mRNA Vaccine Drugs Development Services Revenue by Application (2021-2032)
- 8.4.1 North America mRNA Vaccine Drugs Development Services Revenue by Application (2021-2026)
- 8.4.2 North America mRNA Vaccine Drugs Development Services Revenue by Application (2027-2032)
- 8.5 North America mRNA Vaccine Drugs Development Services Revenue Share by Application (2021-2032)
- 8.6 North America mRNA Vaccine Drugs Development Services Revenue by Country
- 8.6.1 North America mRNA Vaccine Drugs Development Services Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America mRNA Vaccine Drugs Development Services Revenue by Country (2021-2026)
- 8.6.3 North America mRNA Vaccine Drugs Development Services Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe mRNA Vaccine Drugs Development Services Revenue (2021-2032)
- 9.2 Europe mRNA Vaccine Drugs Development Services Revenue by Type (2021-2032)
- 9.2.1 Europe mRNA Vaccine Drugs Development Services Revenue by Type (2021-2026)
- 9.2.2 Europe mRNA Vaccine Drugs Development Services Revenue by Type (2027-2032)
- 9.3 Europe mRNA Vaccine Drugs Development Services Revenue Share by Type (2021-2032)
- 9.4 Europe mRNA Vaccine Drugs Development Services Revenue by Application (2021-2032)
- 9.4.1 Europe mRNA Vaccine Drugs Development Services Revenue by Application (2021-2026)
- 9.4.2 Europe mRNA Vaccine Drugs Development Services Revenue by Application (2027-2032)
- 9.5 Europe mRNA Vaccine Drugs Development Services Revenue Share by Application (2021-2032)
- 9.6 Europe mRNA Vaccine Drugs Development Services Revenue by Country
- 9.6.1 Europe mRNA Vaccine Drugs Development Services Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe mRNA Vaccine Drugs Development Services Revenue by Country (2021-2026)
- 9.6.3 Europe mRNA Vaccine Drugs Development Services Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China mRNA Vaccine Drugs Development Services Revenue (2021-2032)
- 10.2 China mRNA Vaccine Drugs Development Services Revenue by Type (2021-2032)
- 10.2.1 China mRNA Vaccine Drugs Development Services Revenue by Type (2021-2026)
- 10.2.2 China mRNA Vaccine Drugs Development Services Revenue by Type (2027-2032)
- 10.3 China mRNA Vaccine Drugs Development Services Revenue Share by Type (2021-2032)
- 10.4 China mRNA Vaccine Drugs Development Services Revenue by Application (2021-2032)
- 10.4.1 China mRNA Vaccine Drugs Development Services Revenue by Application (2021-2026)
- 10.4.2 China mRNA Vaccine Drugs Development Services Revenue by Application (2027-2032)
- 10.5 China mRNA Vaccine Drugs Development Services Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia mRNA Vaccine Drugs Development Services Revenue (2021-2032)
- 11.2 Asia mRNA Vaccine Drugs Development Services Revenue by Type (2021-2032)
- 11.2.1 Asia mRNA Vaccine Drugs Development Services Revenue by Type (2021-2026)
- 11.2.2 Asia mRNA Vaccine Drugs Development Services Revenue by Type (2027-2032)
- 11.3 Asia mRNA Vaccine Drugs Development Services Revenue Share by Type (2021-2032)
- 11.4 Asia mRNA Vaccine Drugs Development Services Revenue by Application (2021-2032)
- 11.4.1 Asia mRNA Vaccine Drugs Development Services Revenue by Application (2021-2026)
- 11.4.2 Asia mRNA Vaccine Drugs Development Services Revenue by Application (2027-2032)
- 11.5 Asia mRNA Vaccine Drugs Development Services Revenue Share by Application (2021-2032)
- 11.6 Asia mRNA Vaccine Drugs Development Services Revenue by Country
- 11.6.1 Asia mRNA Vaccine Drugs Development Services Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia mRNA Vaccine Drugs Development Services Revenue by Country (2021-2026)
- 11.6.3 Asia mRNA Vaccine Drugs Development Services Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA mRNA Vaccine Drugs Development Services Revenue (2021-2032)
- 12.2 SAMEA mRNA Vaccine Drugs Development Services Revenue by Type (2021-2032)
- 12.2.1 SAMEA mRNA Vaccine Drugs Development Services Revenue by Type (2021-2026)
- 12.2.2 SAMEA mRNA Vaccine Drugs Development Services Revenue by Type (2027-2032)
- 12.3 SAMEA mRNA Vaccine Drugs Development Services Revenue Share by Type (2021-2032)
- 12.4 SAMEA mRNA Vaccine Drugs Development Services Revenue by Application (2021-2032)
- 12.4.1 SAMEA mRNA Vaccine Drugs Development Services Revenue by Application (2021-2026)
- 12.4.2 SAMEA mRNA Vaccine Drugs Development Services Revenue by Application (2027-2032)
- 12.5 SAMEA mRNA Vaccine Drugs Development Services Revenue Share by Application (2021-2032)
- 12.6 SAMEA mRNA Vaccine Drugs Development Services Revenue by Country
- 12.6.1 SAMEA mRNA Vaccine Drugs Development Services Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA mRNA Vaccine Drugs Development Services Revenue by Country (2021-2026)
- 12.6.3 SAMEA mRNA Vaccine Drugs Development Services Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst